Health
Clinical trial testing efficacy of antibody against SARS-CoV-2 begins – Medical Xpress
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
For the BLAZE-1 trial, UChicago is recruiting 22 participants to be treated with the LY-CoV555 antibody developed by Eli Lilly and Company in collaboration with AbCellera. The antibody was first identified by scientists at the National Institute of Allergy and Infectious Diseases and AbCe…
-
Business3 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General6 hours agoAlbanese beats drum on economy as trade clouds gather
-
General5 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General5 hours agoHow a fake expert crashed the World | The West Report